Healthcare Sector

AMGN

Market Tracker

$270.20
-1.49
(-0.55%)
2:40 pm
Next Earnings: (est.) 08/03/23 12:00 am
  • AMGN (Selected)

    Amgen Inc.

AMGN Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

AMGN Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

AMGN Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

AMGN Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

AMGN Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

AMGN Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
06/20/2025 PUT $290.00 3,500 +1,200 +52.17%
06/20/2025 CALL $280.00 2,087 +716 +52.22%
07/18/2025 CALL $260.00 814 +651 +399.39%
06/20/2025 PUT $250.00 1,712 +360 +26.63%
06/20/2025 CALL $270.00 776 +334 +75.57%
06/20/2025 PUT $260.00 1,561 +244 +18.53%
05/16/2025 CALL $260.00 10 -164 -94.25%
05/16/2025 CALL $262.50 0 -200 -100.00%
06/20/2025 CALL $290.00 2,000 -300 -13.04%
05/16/2025 CALL $267.50 17 -413 -96.05%
05/16/2025 CALL $270.00 156 -418 -72.82%
05/16/2025 CALL $265.00 16 -635 -97.54%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

AMGN Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.04% 16.22M 3.66B
Vanguard 500 Index Fund 2.31% 12.33M 2.78B
Vanguard/Primecap Fund 1.71% 9.12M 2.06B
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF 1.31% 7.02M 1.58B
Schwab Strategic Tr-Schwab U.S. Dividend Equity ETF 1.25% 6.7M 1.51B
Fidelity 500 Index Fund 1.09% 5.85M 1.32B
SPDR S&P 500 ETF Trust 1.08% 5.78M 1.3B
SPDR Dow Jones Industrial Average ETF 1.05% 5.6M 1.26B
iShares Core S&P 500 ETF 0.89% 4.76M 1.07B
Capital Income Builder, Inc. 0.89% 4.74M 1.07B

AMGN News

  • Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI

    05/08 11:00 am

    GlobeNewswire Inc.

    Read more
  • Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data

    05/02 03:57 pm

    Benzinga

    Read more
  • Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research®

    05/02 10:00 am

    GlobeNewswire Inc.

    Read more
  • Beat the Nasdaq With This Cash-Gushing Dividend Stock

    05/01 08:30 am

    The Motley Fool

    Read more
  • 4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

    04/26 06:05 pm

    The Motley Fool

    Read more
  • Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

    04/22 05:37 pm

    The Motley Fool

    Read more
  • 3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold

    04/22 09:53 am

    The Motley Fool

    Read more
  • [Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

    04/14 10:00 am

    GlobeNewswire Inc.

    Read more
  • Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline

    04/10 05:59 am

    GlobeNewswire Inc.

    Read more
  • Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide

    04/08 04:48 am

    GlobeNewswire Inc.

    Read more
  • 3 Dividend Stocks to Buy and Hold for the Next Decade

    04/06 06:44 am

    The Motley Fool

    Read more
  • 2 Dividend Stocks to Buy Hand Over Fist in April

    04/05 08:30 am

    The Motley Fool

    Read more
  • Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks

    04/04 10:56 am

    Benzinga

    Read more
  • FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder

    04/04 10:30 am

    Benzinga

    Read more
  • Why Pharma and Biotech Stocks Got Thrashed on Tuesday

    03/25 06:47 pm

    The Motley Fool

    Read more
  • Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

    03/21 12:31 pm

    Benzinga

    Read more
  • Prediction: These 2 Stocks Will Outperform the Market Through 2030

    03/18 09:53 am

    The Motley Fool

    Read more
  • 5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond

    03/17 07:45 am

    The Motley Fool

    Read more
  • Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - Report by Transparency Market Research, Inc.

    03/13 06:00 pm

    GlobeNewswire Inc.

    Read more
  • Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide

    03/12 08:48 am

    GlobeNewswire Inc.

    Read more
  • Is Eli Lilly Stock a Buy?

    03/11 04:10 am

    The Motley Fool

    Read more
  • Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

    03/10 12:50 pm

    Benzinga

    Read more
  • 1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

    03/09 06:20 am

    The Motley Fool

    Read more
  • 3 Magnificent Growth Stocks to Buy in March

    03/08 11:41 am

    The Motley Fool

    Read more
  • International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month

    03/01 09:45 am

    GlobeNewswire Inc.

    Read more
  • This Could Be the Best GLP-1 Stock to Buy in 2025

    02/28 09:45 am

    The Motley Fool

    Read more
  • Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

    02/27 11:04 am

    Benzinga

    Read more
  • These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?

    02/25 05:53 am

    The Motley Fool

    Read more
  • TALTZ’s Rapid Market Ascent Reflects its Unparalleled Ability to Transform the Treatment Landscape for Autoimmune Diseases | DelveInsight

    02/24 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Questex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education

    02/24 11:00 am

    GlobeNewswire Inc.

    Read more
  • Want Decades of Passive Income? Buy This ETF and Hold It Forever.

    02/18 07:15 am

    The Motley Fool

    Read more
  • Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

    02/10 07:15 am

    The Motley Fool

    Read more
  • 3 Fabulous Dividend Stocks to Buy in February

    02/09 03:30 pm

    The Motley Fool

    Read more
  • Paresthesia Treatment Market Outlook: USD 8.0 Billion by 2034, Growing with an Aging Population and Rising Healthcare Expenditures | Analysis by TMR

    02/07 12:39 pm

    GlobeNewswire Inc.

    Read more
  • Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead

    02/05 01:21 pm

    Benzinga

    Read more
  • Aplastic Anemia Global Clinical Trials Review 2024 | Now Available

    02/04 12:00 pm

    GlobeNewswire Inc.

    Read more
  • Recombinant Chemicals Market to Reach US$ 6.7 Bn by 2034, Driven by Rising Demand for Protein-Based Vaccines & Genetic Disorder Treatments – TMR Analysis

    01/31 10:00 am

    GlobeNewswire Inc.

    Read more
  • Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer

    01/27 11:49 am

    GlobeNewswire Inc.

    Read more
  • These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024

    01/25 07:17 am

    The Motley Fool

    Read more
  • Delta-like Ligand 3 (DLL3) Targeted Therapies Market Research 2025: 1 Drug, Imdelltra (Tarlatamab) Available / 10 Drugs by Company, Indication and Phase / Approved Drug Dosage, Sales & Pricing Insight

    01/23 08:51 am

    GlobeNewswire Inc.

    Read more
  • Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?

    01/21 06:34 am

    The Motley Fool

    Read more
  • FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation

    01/17 01:11 pm

    Benzinga

    Read more
  • 7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D Management

    01/17 05:53 am

    GlobeNewswire Inc.

    Read more
  • Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica

    01/17 04:30 am

    GlobeNewswire Inc.

    Read more
  • Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

    01/14 08:25 am

    The Motley Fool

    Read more
  • Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

    01/09 03:12 pm

    Benzinga

    Read more
  • NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries

    01/09 11:53 am

    GlobeNewswire Inc.

    Read more
  • Alzheimer's Disease Diagnostics Research Report 2024-2034: Global Market to Reach $27.87 Billion - Focus on Cost-Effective Alzheimer's Diagnostics Gaining Momentum

    01/09 11:48 am

    GlobeNewswire Inc.

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: